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Dengue virus (DENV) is a mosquito-borne flavivirus that causes
dengue fever in humans, worldwide. Using in vitro cell lines
derived from Aedes albopictus and Aedes aegypti, the primary
vectors of DENV, we report that DENV2/DENV3-infected cells se-
crete extracellular vesicles (EVs), including exosomes, containing
infectious viral RNA and proteins. A full-length DENV2 genome,
detected in arthropod EVs, was infectious to naïve mosquito and
mammalian cells, including human-skin keratinocytes and blood
endothelial cells. Cryo-electron microscopy showed mosquito EVs
with a size range from 30 to 250 nm. Treatments with RNase A,
Triton X-100, and 4G2 antibody-bead binding assays showed that
infectious DENV2-RNA and proteins are contained inside EVs. Viral
plaque formation and dilution assays also showed securely contained
infectious viral RNA and proteins in EVs are transmitted to human
cells. Up-regulated HSP70 upon DENV2 infection showed no role in
viral replication and transmission through EVs. In addition, qRT-PCR
and immunoblotting results revealed that DENV2 up-regulates ex-
pression of a mosquito tetraspanin-domain–containing glycoprotein,
designated as Tsp29Fb, in A. aegyptimosquitoes, cells, and EVs. RNAi-
mediated silencing and antibody blocking of Tsp29Fb resulted in
reduced DENV2 loads in both mosquito cells and EVs. Immunoprecip-
itation showed Tsp29Fb to directly interact with DENV2 E-protein.
Furthermore, treatment with GW4869 (exosome-release inhibitor) af-
fected viral burden, direct interaction of Tsp29Fb with E-protein and
EV-mediated transmission of viral RNA and proteins to naïve human
cells. In summary, we report a very important finding on EV-mediated
transmission of DENV2 from arthropod to mammalian cells through
interactions with an arthropod EVs-enriched marker Tsp29Fb.
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Arthropod-borne diseases are of major concern to mankind.Primary arthropod vectors, such as mosquitoes, transmit
several pathogens, including flaviviruses that cause severe dis-
eases in humans (1, 2). The roles of vector molecules and their
mechanisms in transmission of arthropod-borne flaviviruses from
vector to vertebrate host are not completely understood. Targeting
essential vector molecules used by flaviviruses during transmission
to the vertebrate host is envisioned as the best approach to develop
therapeutics and vaccine candidates (3). Currently, there are no
specific drugs/therapies or vaccines for several of these arthropod-
borne flaviviral infections (4–6). Development of novel and poten-
tial approaches is essential to control flaviviral diseases. Current
research efforts are focused to understand pathogenesis of the
emerging mosquito-borne dengue virus (DENV; serotype 2) and its
detrimental effects in causing numerous human deaths throughout
the world. With regard to the global impact from arthropod-borne
diseases, dengue is the most critical human arbovirus that exists as
four serotypes: DENV1, -2, -3, and 4. The acute asymptomatic ill-
ness (dengue fever) leads to stages of dengue hemorrhagic fever,
dengue shock syndrome, multiple organ failure, and death (6–9).
Recently, the WHO immunization group SAGE (Strategic Advi-
sory Group of Experts) has recommended the use of dengue vac-
cine (a live attenuated tetravalent dengue vaccine CYD-TDV,
named Dengvaxia) developed by Sanofi Pasteur. Apart from this
partially effective vaccine, there are no drugs or pan-vaccines
available for human use to prevent/cross-protect or treat dengue
infections in endemic areas (8–10).
So far, no studies have elucidated whether arthropods secrete
extracellular vesicles (EVs), including small vesicles referred to as
exosomes, and whether pathogens are transmitted from the vector
to the vertebrate host via mosquito-derived EVs. Because of the
occurrence of RNA in the small EVs (11, 12), we hypothesized
whether these EVs are carriers of positive-sense single-stranded
RNA viruses belonging to the family Flaviviridae. Since their dis-
covery in the early 1980s, exosomes have been recognized as small
membrane-bound EVs that act as imperative intercellular messen-
gers carrying and transporting functional RNAs, miRNA, proteins,
and lipids (13–15). EVs are basically of endocytotic origins that are
released from the cells upon fusion of multivesicular bodies with the
cellular membranes (13–15). Recent discoveries of functional RNA
and miRNA within EVs has increased the attention that has led to
the emergence of numerous studies in identifying novel molecules
present in the EVs (13–16). The International Society for Extra-
cellular Vesicles defines exosomes with new nomenclature as small
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extracellular vesicles of 40–120 nm; we have considered exosomes
together with other sized vesicles as EVs in our analysis (17). Our
findings from this current study, showing the presence of the
DENV2 full-length genome and viral proteins in mosquito cell-
derived EVs, provide important data for the current and future
avenues in understanding biology of arthropod EVs in pathogen
transmission. We also determine that arthropod HSP70 (heat-shock
protein 70, a specific EV/exosomal marker in mammals) is induced
in mosquito cells upon DENV2 infection, but its inhibition had no
effect in blocking viral replication and transmission via EVs. In
addition, identification of a tetraspanin domain-containing glyco-
protein, Tsp29Fb, a putative ortholog of human CD63 (mammalian
EVs/exosome marker), showed conservation in EV-mediated
communication, suggesting an essential therapeutic strategy in
blocking transmission of DENV2 from arthropods to humans.
Collectively, this study is not only critical in understanding the
molecular basis of the modes of flaviviral transmission from the
arthropod vector, but may also potentially lead to the development
of better strategies to interfere with the life cycle of this and perhaps
other medically important vectors.
Results
Mosquito Cell-Derived EVs Contain DENV2 Infectious RNA and Proteins.
We used Aedes albopictus and Aedes aegypti mosquito cell lines (C6/
36 and Aag-2, respectively) as a model to understand the interac-
tions of DENV (serotype 2) with mosquito vectors. DENV2 [mul-
tiplicity of infection (MOI) 5] readily infected the C6/36 cell line
with significantly (P < 0.05) increased viremia at 72 and 96 h
postinfection (hpi) in comparison with 48 hpi (SI Appendix, Fig.
S1A). Next, we analyzed whether C6/36 cells secrete EVs, including
small EVs, and if mosquito-borne flaviviruses use those EVs as
modes of pathogen transmission. C6/36 cell-derived EVs contained
DENV2 capsid mRNA loads in a time-dependent manner, with
increased viral loads at 72 hpi (MOI 5), compared with the early
tested time points of 24 and 48 hpi (SI Appendix, Fig. S1B). In
addition, we determined DENV2 loads in A. aegypti mosquitoes at
different time points (24, 48, and 72 hpi) of infection (SI Appendix,
Fig. S1C). Because of increased viral loads (both in cell line and in
vivo), we selected 72 hpi as the time point for the isolation of EVs
from mosquito cells. EVs were isolated by either a density-gradient
(DG) centrifugation technique [OptiPrep (DG-EVs isolation) as
described in refs. 18 and 19] or by using a commercially available
exosome isolation reagent and following the manufacturer’s in-
structions (ThermoScientific), or by differential ultracentrifugation
with slight modifications and longer spin times for 155 min (SI
Appendix, Fig. S2) (11, 15, 18–23). Detailed protocols for EV iso-
lation by DG-Exo and ultracentrifugation methods are shown as
schematics (SI Appendix, Fig. S2). Cryo-electron microscopy (cryo-
EM) performed on C6/36 cell-derived EV fractions showed the
presence of purified mosquito EVs with the size range of 30–
250 nm in diameter (Fig. 1A), which are similar to EVs isolated
from mammalian cells (11, 15, 18, 24–26). Quantitative analysis of
the heterogeneous population of arthropod-derived EVs showed
the highest percentage to be in sizes between 50 and 100 nm (in
diameter) in both uninfected and DENV2-infected groups (SI Ap-
pendix, Fig. S3 A and B). However, DENV2-infected cell-derived
EVs had increased (50–100 nm) and decreased (100–150 nm)
percentage sizes in comparison with the uninfected control (SI
Appendix, Fig. S3 A and B). The observation of lower percentage
of larger EVs (in the size range of 200–350 nm) upon DENV2
infection in comparison with the uninfected group suggests that
DENV2 may stimulate production of smaller-sized EVs (SI
Appendix, Fig. S3 A and B). Countings of total number of EVs from
uninfected or DENV2-infected (MOI 5, 72 hpi) cryo-EM images
collected from at least three independent isolations showed no
significant differences (SI Appendix, Fig. S3C). Because the physical
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Fig. 1. EVs derived frommosquito cells contain DENV2/DENV3 RNA and proteins. (A) Cryo-EM images showing EVs isolated from uninfected or DENV2-infected (MOI
5, 72 hpi) C6/36 cells. [Scale bar, 100 nm (in diameter).] (B) Immunoblotting gel image from DG-EV-iso preparation showing enhanced DENV2 E-protein levels and
HSP70 in fractions 4–6. EVs derived from uninfected cells serve as control. Total protein profiles from both groups are shown for comparison. Fraction number and
calculated iodixanol density (g/mL) is shown for reference. qRT-PCR analysis showing DENV2 (C) or DENV3 (D) loads in EVs isolated from C6/36 cells at 72 hpi (n = 5 in
both panels). DENV2/DENV3 capsid mRNA levels were normalized to mosquito actin levels. P value determined by Student’s two-tail t test is shown. (E) Immuno-
blotting analysis showing detection of DENV2 E-protein and NS1 in EV fraction and total lysates from whole cells prepared from uninfected (UI) or infected (I) C6/
36 cells at 72 hpi (MOI 5). (F) DENV3-specific E-protein in EVs and total cell lysates from uninfected (UI) or infected (I) C6/36 cells at 72 hpi (MOI 5) is shown. Protein sizes
are indicated as kilodaltons. Images showing total protein profiles serve as controls in both E and F.















characterization and quality of the EVs as revealed by cryo-EM
imaging was very pure, we quantified the EVs through estimat-
ing total protein amounts by Bradford protein assay (BCA). EVs
isolated from different numbers of plated cells (104, 105, 106, 107,
and 1 × 108), showed linear increase in the concentration of total
EV protein (SI Appendix, Fig. S3 D and E). No differences were
observed in EV total protein concentrations from DENV2-
infected or uninfected controls (SI Appendix, Fig. S3 D and E).
These data correlated with the observation of no differences in the
total number of EVs between DENV2-infected or uninfected
groups (SI Appendix, Fig. S3C). In both groups, increasing density of
cells showed higher increments in total protein concentrations of
EVs (SI Appendix, Fig. S3 D and E).
Next, we collected six different fractions from the DG-EV
isolation method (SI Appendix, Fig. S2A). Mosquito HSP70 was
detected in 20 μL of each of the infected or uninfected EV
fractions from 2 to 6, with increased levels in fraction 4 (Fig. 1B).
No HSP70 was detected in fraction 1 from EVs isolated from
uninfected or DENV2-infected groups (Fig. 1B). However, the
level of HSP70 was found to be increased in fractions isolated
from DENV2-infected EVs in comparison with the uninfected
fractions that served as controls. (Fig. 1B). We found that
DENV2 envelope (E)-protein (detected by highly cross-reactive
4G2 monoclonal antibody that recognizes flavivirus E-protein,
both endogenous and glycosylated forms) was enhanced in in-
fected EV fraction 5 in comparison with the other fractions (Fig.
1B). Immunoblotting also showed detection of both DENV2-
glycosylated (Fig. 1B, Upper band) and endogenous (Fig. 1B,
Lower band) E-protein in fraction 5. As expected, DENV2 E-
protein was not detected in any uninfected controls (Fig. 1B).
The Ponceau S-stained images showed total protein profile in
each fraction (Fig. 1B). Density of each fraction was estimated by
a control density-gradient experiment with similar volume of
0.25 M sucrose/10 mM Tris pH 7.5 that was run in parallel to
determine the iodixanol concentrations. In addition, we per-
formed DG-EV isolation by filtering the culture supernatants
with 0.22-μM filters that resulted in 12 fractions. Similar results
were obtained with filtered samples, where enhanced amounts of
E-protein were detected in higher density of 10, 11, and 12 EV
fractions (SI Appendix, Fig. S3F). HSP70 was detected in all
samples with increased amounts in fractions 10 and 11 (SI Ap-
pendix, Fig. S3F). Ponceau S-stained images showed a total
protein profile in each fraction (SI Appendix, Fig. S3F).
Next, we determined if mosquito cell-derived EVs contain the
full-length DENV2 genome. PCR analysis (with oligonucleotides
producing overlapping amplicons covering entire DENV2 se-
quence) noted the presence of the full-length DENV2 genome in
C6/36 cell-derived EVs (SI Appendix, Fig. S4A). Fragments 1–10
amplified products of 1,102 bp, 1,110 bp, 1,124 bp, 1,114 bp,
1,118 bp, 1,141 bp, 1,104 bp, 1,135 bp, 1,110 bp, and 1,048 bp (SI
Appendix, Fig. S4A). Fragment 11 (3′ end of the genome) am-
plified multiple products, including the expected size of 717 bp
(SI Appendix, Fig. S4A). Several PCR attempts to amplify fragment
11 consistently showed an appearance of multiple bands, perhaps
suggesting the loop nature of the 3′ end of the genome (SI Ap-
pendix, Fig. S4A). We have been able to successfully show the
presence of entire DENV2 genome inside mosquito EVs. Quanti-
tative real-time PCR (qRT-PCR) also showed DENV2 total capsid
mRNA in EVs derived from infected (MOI 5, 72 hpi) C6/36 cells
(Fig. 1C). To address if other serotypes of DENV are also present
and transmitted easily as being part of the EVs, we tested
DENV3 viral RNA in EVs. DENV3-infected (MOI 5, 72 hpi) C6/
36 cell-derived EVs also showed the presence of viral capsid
mRNA, suggesting EVs as mediators of perhaps all serotypes of
DENVs (Fig. 1D). In addition, DENV2 E- and nonstructural 1 (NS1)
proteins were also detected in C6/36 cell lysates and EVs (Fig. 1E). It
was noted that E-protein levels were enhanced in EVs in comparison
with cell lysates at 72 hpi, whereas no differences were observed with
NS1 protein levels in either EVs or total cell lysates (Fig. 1E). Fur-
thermore, we detected enhanced E-protein levels in DENV3-infected
(MOI 5, 72 hpi), C6/36 cell-derived EVs in comparison with the total
cell lysates (Fig. 1F). Coomassie-stained gel images show the total
protein profiles in both DENV2 and DENV3 groups (Fig. 1 E and
F). The observation of a reduced number of protein bands in both
DENV2 and DENV3 EV fractions in comparison with the whole-cell
lysate fractions, respectively (Fig. 1 E and F), suggests a restricted
regulation, sorting, and export of proteins into mosquito EVs.
DENV2 RNA and Proteins Are Securely Contained Inside the EVs. To
not rule out the possibility of DENV2 particles being present either
inside or outside of the EVs, we performed cryo-EM analysis on C6/
36 cell-derived EV fractions (six). DENV2-infected (MOI 5, 72 hpi)
C6/36 cell-derived EV fractions did not show any viral particles or
virions either inside or outside of these EV fractions (SI Appendix,
Fig. S4B). These data suggest that viral RNA and proteins are
perhaps sufficient to modulate the infection of naïve recipient cells.
We also tested if viral RNA is binding to the outside of the EVs and
may be then transmitted to the recipient cells. We did not find any
differences in viral loads of naïve C6/36 cells upon incubation with
EVs prepared from DENV2-infected (MOI 5, 72 hpi) RNaseA-
treated (5 μg/mL, for 15 min, at 37 °C) or untreated groups (SI
Appendix, Fig. S5A). Naïve C6/36 cells incubated with EVs derived
from uninfected cells (as independent batch), but treated with
RNase A, were kept as internal control (SI Appendix, Fig. S5A). In
another independent RNaseA-treatment assay, we included MOI
5 of DENV2 laboratory virus stocks [collected from 14 d post-
infection (dpi) C6/36 cell culture supernatants] along with infectious
EVs (collected from DENV2 infected C6/36 cells, MOI 5, 72 hpi)
for comparison (SI Appendix, Fig. S5B). We obtained reproducible
results with no differences in viral loads in naïve C6/36 cells upon
incubation with EVs or laboratory viral stocks prepared from
DENV2-infected RNaseA-treated or untreated groups (SI Appendix,
Fig. S5B). Because the viral genome is deep inside and not accessible
in enveloped DENV2, RNaseA treatments showed no effects. To
confirm that the viral proteins too are contained inside the mosquito
cell-derived EVs, and are not present in the PBS suspensions that are
free or depleted of EVs, we designed and performed an E-protein
4G2-antibody bead binding assay to confirm that viral E-protein is
not present outside of the EVs as a contaminant. No significant (P <
0.05) differences were observed in viral loads between DENV2-
infected (MOI 5, 72 hpi) EV fractions treated with either 4G2 an-
tibody (that binds to viral E-protein) or with relevant isotype control
antibody or the untreated controls (SI Appendix, Fig. S5C). We also
tested the DENV2 laboratory stocks (MOI 5) as controls that showed
reduced DENV2 loads in C6/36 cells in comparison with the isotype
antibody-treated or untreated controls (SI Appendix, Fig. S5D). These
data served as a positive control for the EV group. Taken together,
these data suggest that E-protein is securely contained inside
the arthropod EVs.
To further confirm that viral E-protein is contained inside the
EVs, we performed native-PAGE followed by immunoblotting with
4G2 antibody on EV fractions (collected from DENV2-infected,
MOI 5, 72 hpi cells) treated with 0.1% Triton X-100 (a detergent
that lyse the EV lipid bilayer membrane) for 30 min at room
temperature, or treated with freeze/thaw cycle (three rounds of
freezing, for 1 h each time, at −80 °C). Untreated samples (held at
4 °C) served as controls. An enhanced level of DENV2 E-protein
(in native state at ∼200–250 kDa) was detected in Triton X-100–
treated EV fractions in comparison with the levels in untreated
fractions (SI Appendix, Fig. S5E). The lower molecular mass of E-
protein in Triton X-100–treated EV fractions indicated the lysis and
separation of higher molecular structures that may exist as dimers
or oligomers (SI Appendix, Fig. S5E). Ponceau S-stained images
showed the total protein profile and served as control (SI Appendix,
Fig. S5E). In addition, immunostaining analysis with 4G2 antibody
showed that EVs treated/lysed with 0.1% of Triton X-100 had a
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higher fluorescent signal for DENV2 E-protein in comparison with
untreated EV fractions (SI Appendix, Fig. S5F). As expected, E-
protein staining was enhanced upon permeabilization of EVs, sug-
gesting the presence of E-protein inside EVs (SI Appendix, Fig.
S5F). ELISA with 4G2 antibody further supported the native-
PAGE and immunostaining analyses, where higher loads of
DENV2 E-protein were detected when EVs were permeabilized
with 0.1% of Triton X-100 in comparison with untreated controls
(SI Appendix, Fig. S5G). The lysis of EV lipid-bilayer would release
the viral E-protein contained inside the EVs, thereby resulting in
enhanced detection of E-protein upon permeabilization with Triton
X-100. Overall, these data suggest that DENV2 RNA and proteins
are securely contained inside the arthropod EVs.
DENV2 Infectious RNA and Proteins Are Transmitted to Mosquito,
Murine, and Human Cells Through Arthropod EVs. To address
whether DENV2 RNA and proteins contained in mosquito
cell-derived EVs are viable and capable to infect arthropod/
vertebrate host cells and form infectious particles, we used EV
fractions (pellet) and EV-free or EV-depleted supernatant
(EDS; generated during EV pelleting and before PBS wash) (SI
Appendix, Fig. S2B) fractions isolated from 72 hpi (MOI 5) C6/
36 cells. Virus-dilution assays performed on naïve C6/36 cells
with infectious EV fractions (dilution 3; 1,000-fold diluted)
showed enhanced fluorescent signal for E-protein detected by
4G2 antibody in comparison with EDS-treated cells (Fig. 2A).
Furthermore, EV fractions in dilution one (10-fold) showed
similar enhanced fluorescence signal for E-protein in compari-
son with EDS fractions (SI Appendix, Fig. S6A). The dilutions of
10 and 1,000 correspond to 12.6 μg and 0.126 μg of total EVs
protein, respectively, as estimated by the BCA method. These
data suggest that DENV2 RNA and proteins contained inside
EVs are highly infectious. In addition, infectious mosquito EV
fractions and EDS were tested in plaque assays (as described in
SI Appendix, SI Materials and Methods) to determine the in-
fectivity and replication of viral RNA and formation of viable
plaques in Vero cells. First, we determined infection kinetics
(MOI 5) in Vero cells and noted that an increased peak of
DENV2 infection was at 96 hpi (SI Appendix, Fig. S6B). Mos-
quito cell-derived infectious EV pellet fractions yielded plaques
at dilutions of 1:10 that were too numerous to count, and around
25–30 plaques at a dilution of 1:100, and fewer than 5 plaques in
dilutions of 1:1,000 (Fig. 2B). No plaques were detected in plates
where Vero cells were treated with the EDS undiluted fractions
collected before pelleting the EVs (Fig. 2B). Plaque assays fur-
ther confirmed that mosquito cell-derived EVs contain DENV2
RNA and proteins, capable of replication and forming viable
viral plaques that are highly infectious to the mammalian cells.
We analyzed whether infectious mosquito EVs are capable of
transmission of DENV2 to other cells. First, infection of DENV2
in several other cell lines was assessed, which showed detect-
able loads at 72 hpi (MOI 5) (SI Appendix, Fig. S6 C–E). Next,
we analyzed the ability of DENV2 infectious EVs to infect
naïve C6/36 cells, mouse monocyte-derived dendritic cells (Mo-
DCs), human-skin keratinocytes (HaCaT cells), and human
blood endothelial cells (HUVEC). Because of detectable loads
of DENV2 at 72 hpi (MOI 5), we considered infecting the mam-
malian cells via infectious EVs collected from 72 hpi DENV2-infected
(MOI 5) C6/36 cells. These infectious EVs showed the transmission
and reinfection ability to infect naïve mosquito C6/36 cells, mouse
Mo-DCs, HaCaT cells, and HUVEC cells (Fig. 2C). Detectable viral
loads were found in all of these tested cell lines at 72 h postincubation;
however, significant (P < 0.05) DENV2 loads were noted in mouse
and human cells in comparison with mosquito cells (Fig. 2C). No viral
loads were detected in any tested cell lines incubated with EDS
fractions (Fig. 2C). Overall, these results suggest that DENV2 viral
RNA and proteins exit mosquito cells via EVs, and that these
infectious EVs mediate transmission of DENVs to human cells.
Role of Mosquito HSP70 in EV-Mediated DENV2 Transmission. This
intracellular molecular chaperone, required for protection and
recovery from stress, is secreted via unknown exocytotic path-
ways and trafficked into EVs (27, 28). HSP70 has also been iden-
tified and characterized fromA. aegypti and A. albopictusmosquitoes
(29, 30). Our study demonstrated that arthropod HSP70 is present
in EVs derived from mosquito cells. To understand the importance
of HSP70 in mosquito EVs andDENV2 transmission, we investigated
the role of two isoforms of hsp70 genes (GenBank accession nos.
JN132154 and XM_019672019) present in the A. albopictus genome.
qRT-PCR analysis revealed that both hsp70 isoforms were up-
regulated in C6/36 cells upon DENV2 infection (MOI 5) at 48 h
and 72 hpi in comparison with 24 hpi and uninfected controls
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Fig. 2. EVs derived from mosquito cells are infectious and transmit DENV2 to both arthropod and mammalian cells. (A) Fluorescent microscopic images
showing detection of E-protein in C6/36 cells infected via EVs derived from independent batch of DENV2-infected (MOI 5; 72 hpi) C6/36 cells. EDS-treated cells
serve as control (n = 5). (Scale bar, 200 μm.) (B) Quantitative assessment of number of plaques on Vero cells treated with EVs (in different dilutions) or (EDS)
fractions (as similar dilution) derived from DENV2-infected (MOI 5, 72 hpi) C6/36 cells are shown. TNTC indicates “too numerous to count” (n = 2). (C) qRT-PCR
analysis showing viral loads at 72 hpi in naïve C6/36 or mouse dendritic or human HaCaT or HUVEC cells treated with EVs or EDS fractions derived from DENV2-
infected (MOI 5, 72 hpi) C6/36 cells are shown (n = 3 for each cell line). ND indicates not detectable. Depending on the cells that were used, DENV2 capsid
mRNA levels were normalized to mosquito, mouse, or human actin levels.















(SI Appendix, Fig. S7 A and B). No detection of hsp70 transcript
(GenBank accession no. JN132154) was observed in uninfected or
DENV2-infected C6/36 cell-derived EVs. Even though, expression of
the other hsp70 transcript (GenBank accession no. XM_019672019)
was clearly evident in EVs, no significant (P > 0.05) difference was
noted between uninfected or DENV2-infected groups (SI Appendix,
Fig. S7C). Immunoblotting analysis showed an increased level of
HSP70 in EVs isolated fromDENV2-infected (MOI 5) cells at 24 hpi
in comparison with 48 and 72 hpi time points and uninfected controls
(SI Appendix, Fig. S7D). In addition, no differences in HSP70 levels
were noted in uninfected or DENV2-infected C6/36 cell lysates
at all tested time points (24, 48, and 72 hpi) and their respective
uninfected controls (SI Appendix, Fig. S7D). Coomassie-stained
gel images show the total protein profiles in EVs and total cell
lysates (SI Appendix, Fig. S7D).
Next, we determined the role of mosquito HSP70 in EV-
mediated DENV2 transmission. VER-155008 is an adenosine-
derived inhibitor of the 70-kDa families of HSPs that target the
ATPase binding domain (31, 32). qRT-PCR analysis showed that
C6/36 cells treated (for 4 h) with VER-155008 inhibitor (at
10 and 20 μM), followed by infection with DENV2 (MOI 5, for
72 hpi) had significantly (P < 0.05) reduced levels of hsp70
(XM_019672019) transcript levels, in comparison with the mock-
(DMSO) treated group (SI Appendix, Fig. S7E). No differences
were observed in XM_019672019 levels in EVs derived from these
inhibitor-treated and DENV2-infected C6/36 cells (SI Appendix,
Fig. S7E). Furthermore, treatment with VER-155008 inhibitor at
tested doses of 10 and 20 μM, in comparison with the respective
mock controls, showed no differences in DENV2 loads (at 72 hpi)
in both total cell and EV lysates (SI Appendix, Fig. S7F). In addi-
tion, we tested the effects of VER-155008 inhibitor-treated EVs
(derived from DENV2-infected, MOI 5, 72 hpi, C6/36 cells) and
EDS from the same batch of preparations (SI Appendix, Fig. S7G)
on naïve C6/36 cells incubated with infectious EVs for 72 hpi. No
differences were found in DENV2 loads in the inhibitor-treated
group compared with the respective mock controls (SI Appendix,
Fig. S7G). Furthermore, we did not observe any differences in
DENV2 loads of naïve C6/36 cells incubated with EDS fractions in
comparison with their respective mock controls (SI Appendix, Fig.
S7G). As expected, DENV2 loads in EV fractions showed signifi-
cant (P < 0.05) differences compared with the EDS fractions (SI
Appendix, Fig. S7G). These data suggest the up-regulation of mos-
quito HSP70 as arthropod stress response during DENV2 infection,
but inhibition of this critical chaperone does not regulate viral rep-
lication and transmission through EVs.
Identification of Mosquito EV Marker Tsp29Fb, a Tetraspanin Domain-
Containing Glycoprotein. Several studies have considered proteins,
such as human CD63, that are associated with membranes of in-
tracellular vesicles as classic markers of EVs/exosomes (33–36).
Lötvall et al. (17) have shown that CD63 is present on both EVs/
exosomes and can thus be a marker for both large and small vesicles.
CD63 belongs to the tetraspanin family of transmembrane-domain
proteins (35). Using a human CD63 primary amino acid sequence
(GenBank accession no. AHI151903) as a query in the VectorBase,
we identified tetraspanin domain-containing mosquito orthologs in
both A. aegypti (AAEL012532-RA) and A. albopictus (AALF020630-
RA) and designated these orthologs as Tsp29Fb. ClustalW alignment
of an A. aegypti Tsp29Fb amino acid sequence (SI Appendix, Fig. S8A)
revealed 89% identity with A. albopictus Tsp29Fb and 51% identity
with Drosophila melanogaster tetraspanin 29Fb (GenBank accession
no. AAF90138). In addition, A. aegypti Tsp29Fb showed 28% and
27% identity (SI Appendix, Fig. S8A) with human and mouse CD63
(GenBank accession no. CAJ18387), respectively. Furthermore, the
phylogenetic analysis revealed that A. aegypti Tsp29Fb comes within
the same clade with A. albopictus Tsp29Fb and D. melanogaster tet-
raspanin 29Fb, whereas human and mouse CD63 counterparts form
a different clade (SI Appendix, Fig. S8B). The domain analysis of
A. aegypti Tsp29Fb primary amino acid sequences revealed the pres-
ence of the tetraspanin domain (amino acids 15–238), four trans-
membrane regions (amino acids 19–41, 56–78, 90–112, 211–233), four
myristoylation sites (amino acids 37–47, 76–82, 92–98, 228–234), and
two glycosylation sites (amino acids 125–129, 168–172) (SI Appendix,
Fig. S8C). Identification of Tsp29Fb in the mosquito genome suggests
the presence of a putative EV marker in arthropods.
DENV2 Infection Up-Regulates Tsp29Fb Levels in Mosquitoes, in EVs,
and in Cells. To understand the role of human CD63-like tetra-
spanin domain-containing arthropod EV marker, Tsp29Fb, we
first analyzed the expression levels of this molecule. In DENV2-
infected A. ageypti mosquitoes (in vivo), we found that tsp29Fb
mRNA (accession no. AAEL012532-RA) loads were signifi-
cantly (P < 0.05) up-regulated at all tested time points of 24, 48,
and 72 hpi, in comparison with the uninfected controls (Fig. 3A).
We also tested the expression of tsp29Fb mRNA in Aag-2 cells,
derived from A. aegypti mosquitoes (37). qRT-PCR analysis
showed that in both Aag-2 cell-derived EVs and in cells, tsp29Fb
(accession no. AAEL012532-RA) transcripts were up-regulated
upon DENV2 infection at the tested time points (48 and 72 hpi
in EVs or Aag-2 cells), compared with the uninfected controls
(Fig. 3 B and C). qRT-PCR analysis further revealed a signifi-
cantly (P < 0.05) higher mRNA transcript of tsp29Fb (accession
no. AALF020630-RA) at 24 and 48 hpi in C6/36 cell-derived
EVs (Fig. 3D), and at 48 and 72 hpi in whole-cell lysates (Fig.
3E). We first determined that human CD63 antibody with a
large tetraspanin epitope region showed high cross-reactivity to
Tsp29Fb, the arthropod homolog with greater conservation and
similarity to the vertebrate CD63. Immunoblotting performed on
C6/36 cell-derived EV fractions and whole-cell lysates at differ-
ent time points of 24, 48, and 72 hpi, showed an increase in
Tsp29Fb protein levels in DENV2-infected (MOI 5) lysates in
comparison with the uninfected controls (Fig. 3F). Furthermore,
these data correlated with the capsid mRNA transcript loads noted
in EVs and C6/36 cell lysates (Fig. 3 D and E). In addition, we also
noted that an increased dose of DENV2 (with different MOI; MOI
from 1 to 5) also affected Tsp29Fb loads in both EVs and total cell
lysates (Fig. 3G). Densitometry analysis from EVs and total
cell lysates [tested time points (48 and 72 hpi) and MOI (1 and 5)
dose–response] showed the quantitative differences in Tsp29Fb
levels observed between DENV2-infected and uninfected controls
(SI Appendix, Fig. S9). E-protein loads increased with both the in-
fection time course of 24, 48, and 72 hpi, and with the higher in-
fectious doses (MOI 1–5, 72 hpi) in both DENV2-infected EVs and
total cell lysates in comparison with the uninfected control (Fig. 3 F
and G). Total protein profiles in all four panels served as loading
controls (Fig. 3 F and G). These data show that Tsp29Fb is up-
regulated both in vivo and in vitro upon DENV2 infection.
Tsp29Fb, an Arthropod EV Marker, Directly Interacts with DENV2
Envelope Protein. To characterize the role of Tsp29Fb in facili-
tating DENV2 infection and transmission, we analyzed if this
putative arthropod EV marker directly interacts with DENV2 E-
protein. Immunoprecipitation (IP) performed with highly cross-
reactive human CD63 antibody and DENV2-infected (MOI 5,
72 hpi) cell-derived EVs and whole-cell lysates (suspended in
modified RIPA protein lysis buffer; 150 μg as input in each
group) showed the presence of DENV2 E-protein by immuno-
blotting with 4G2 antibody (Fig. 3H). Direct binding of Tsp29Fb
to DENV2 E-protein was enhanced in cell lysates in comparison
with the EV lysates, perhaps due to the presence of enhanced
Tsp29Fb protein (Fig. 3H). As expected, no E-protein signal was
detected in uninfected controls processed together for IP (Fig.
3H). To exclude the possibility that direct interaction or binding
of Tsp29Fb to DENV2 E-protein is not due to any E-protein
contamination from EVs pelleted in PBS suspensions, we per-
formed an independent IP assay on intact EVs suspended in PBS
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instead of modified RIPA protein lysis buffer. IP of Tsp29Fb
on PBS suspended intact arthropod EVs (freshly isolated) us-
ing human CD63 antibody followed by immunoblotting with
4G2 antibody again detected the precipitation of DENV2 E-
protein in both mosquito cell-derived EV fractions and whole-
cell lysates (we used 500 μg as input in each group for IP with
PBS suspended EV fractions) (Fig. 3I). We noted enhanced
binding of Tsp29Fb with viral E-protein in cell lysates in com-
parison with the EV fractions (Fig. 3I) that correlated with a
previous IP assay performed on EV fractions resuspended in
modified RIPA buffer (Fig. 3H). Coomassie blue-stained gel
images showing total protein profile of input lysates used for IP
served as controls (Fig. 3 H and I). Immunofluorescence merged
images showed colocalization of Tsp29Fb (SI Appendix, Fig.
S10A, green) with DENV2 E-protein (SI Appendix, Fig. S10A,
red) in C6/36-infected cells (MOI 5, 72 hpi). Uninfected C6/
36 cells and nuclei-stained (DAPI) images (along with phase-
contrast) served as controls (SI Appendix, Fig. S10A). In addition,
we also found that Tsp29Fb neither interacts nor coprecipitates with
actin in either DENV2-infected (MOI 5, 72 hpi) EVs or total cell
lysates (SI Appendix, Fig. S10B). These data served as a negative
control for the direct interaction of Tsp29Fb with DENV2 E-
protein (SI Appendix, Fig. S10B). We have been able to detect ac-
tin protein in both cells and EVs lysates (resuspended in RIPA
buffer) used as input for the IP assay (SI Appendix, Fig. S10C).
These data suggest the presence of actin in input lysates that neither
interact nor coprecipitate with Tsp29Fb. Taken together, these data
suggest that arthropod EV marker Tsp29Fb directly interacts with
DENV2 E-protein, perhaps to facilitate infection and transmission
from vector to the vertebrate host.
Silencing or Blocking of Tsp29Fb Reduces DENV2 Infection. We per-
formed silencing studies, to understand the importance of Tsp29Fb in
DENV2 pathogenesis and in transmission of infectious EVs to the
vertebrate host. We selected the transfection-friendly Aag-2 cells that
contain proteins involved in the RNAi pathway (6, 37). First, we
amplified a 252-bp fragment from an A. aegypti mosquito cDNA
sample and cloned it into the BglII and KpnI sites of the
L4440 double T7 Script II vector (38) (SI Appendix, Fig. S11A andB).
Silencing of tsp29Fb (by transfection with double-stranded RNA)
showed significantly (P < 0.05) decreased tsp29Fb mRNA in Aag-
2 cells in comparison with the mock-transfected group (Fig. 4A).
Lower numbers of tsp29Fb transcripts were exported to the EVs de-
rived from these cells (Fig. 4A). We also found that DENV2 loads
(MOI 5, 24 hpi) were significantly (P < 0.05) reduced in both EVs
and Aag-2 cell lysates upon silencing of tsp29Fb, in comparison with
the mock-transfected controls (Fig. 4B). Immunoblotting analysis
revealed similar results with reduced E-protein and Tsp29Fb protein
loads in both Aag-2 cell-derived EVs and total cell lysates upon
treatment with tsp29Fb-dsRNA in comparison with the mock-treated
controls (Fig. 4C). Densitometry analysis from total cell and EV ly-
sates showed the quantitative differences in Tsp29Fb protein levels
observed between the DENV2-infected (MOI 5, 24 hpi) and un-
infected controls (SI Appendix, Fig. S11C). Total protein profiles
shown by Coomassie-stained gel served as loading controls (Fig. 4C).
Furthermore, we tested the functional-blocking effects of highly cross-
reactive human CD63 antibody in mosquito cells. qRT-PCR data
showed that cells treated (2 h) with either 5 or 10 μg of human
CD63 antibody, followed by infection with DENV2 (MOI 5), showed
significantly (P < 0.05) reduced viral loads (at 72 hpi) in both C6/
36 cell-derived EVs (Fig. 4D) and in cells (Fig. 4E). Immunoblotting
analysis revealed dramatic reduction in the DENV2 E-protein loads
in both 5 and 10 μg of CD63 antibody-treated mosquito cell-derived
EVs and cell lysates, in comparison with the untreated controls (Fig.
4F). Total protein profiles shown by Coomassie-stained gels served
as controls (Fig. 4F). Noticeable differences observed with CD63
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Fig. 3. DENV2 induces expression of Tsp29Fb, a putative EV-enriched marker on mosquito cells. (A) qRT-PCR analysis showing expression of A. aegypti Tsp29Fb in
uninfected (UI) or DENV2-infected (I) whole mosquitoes at 24, 48, and 72 hpi (n = 4), or in EVs (B) isolated from an uninfected (UI) or DENV2-infected (MOI 5) in
vitro cell line or in Aag-2 whole-cell lysates at 48 and 72 hpi (n = 4, in both EVs or cell-lysate panels) (C). qRT-PCR analysis showing expression of A. albopictus
Tsp29Fb ortholog in EVs (D) isolated from uninfected (UI) or DENV2-infected (MOI 5) C6/36 cells or in whole-cell lysates (E) at 24, 48, and 72 hpi (n = 8, in both
EVs or cell-lysate panels). Tsp29Fb or DENV2 capsid mRNA levels were normalized to mosquito actin levels. P value determined by Student’s two-tail t test is
shown. (F) Immunoblotting analysis showing levels of Tsp29Fb and viral E-protein in EVs derived from uninfected (UI) or DENV2-infected (MOI 5) C6/36 cells or in
whole-cell lysate at 24-, 48-, and 72-hpi time points. (G) Immunoblotting analysis showing levels of Tsp29Fb and viral E-protein in EVs derived from uninfected (UI)
or DENV2-infected (MOI 5, 72 hpi) C6/36 cells or in whole-cell lysates upon DENV2 infection with different viral doses (MOI 1–5) is shown. Immunoblotting analysis
of CD63 (Tsp29Fb) IP proteins in RIPA (H) or in 1× PBS buffer (I) with 4G2 antibody showing detection of viral E-protein in EVs or whole-cells lysates derived from
DENV2-infected (MOI 5, 72 hpi) C6/36 cells. Uninfected cells were used as controls in all assays. Gel images showing total protein profiles in F–I serve as loading
control for respective immunoblots. Tsp29Fb and DENV2 E-protein molecular mass is indicated as kilodaltons.















antibody treatments suggest that blocking of mosquito ortholog
Tsp29Fb function reduces DENV2 loads in cells and that ultimately
reduces transmission of viral RNA and proteins via infectious EVs.
GW4869 Inhibitor Reduces DENV2 Loads, Transmission, and Tsp29Fb
Interactions with the Viral E-Protein. GW4869 (dihydrochloride
hydrate) is a cell-permeable but selective inhibitor for neutral
sphingomyelinase (an essential enzyme required for EV pro-
duction and release). Treatment of C6/36 cells with GW4869
at different concentrations (10, 15, and 20 μM) followed by
DENV2 infection (MOI 5, 72 hpi) showed significantly (P < 0.05)
reduced capsid transcript loads in EVs, compared with the DMSO
control (Fig. 4G). Similar results were obtained with immuno-
blotting analysis using 4G2 antibody that showed reduced levels of
DENV2 E-protein at 18 and 24 hpi, and the tested concentrations
(5, 10, and 15 μM) in both infected (MOI 5) C6/36 cell-derived
EVs and cell lysates in comparison with the DMSO controls (Fig.
4H). In both mosquito cells and EVs, the reduction in E-protein
loads was much affected at 24 hpi (15-μM treatments) in com-
parison with the 18-hpi time point, suggesting that higher amounts
and times of incubation with GW4869 had severe effects on
DENV2 infection and transmission (Fig. 4H). Total protein pro-
files shown by Coomassie-stained gels served as controls (Fig. 4H).
Infection of naïve C6/36 cells with EVs derived from DENV2-
infected (MOI 5, 72 hpi) mosquito cells treated with 15 μM of
inhibitor or the DMSO-treated control group showed that treat-
ment with GW4869 not only reduced DENV2 viral RNA repli-
cation but also transmission to naïve C6/36 cells in comparison
with the DMSO controls (Fig. 4I). Transwell assays performed on
naïve/uninfected C6/36 cells [plated on upper chambers or inserts
that were infected via EVs collected from an independent batch of
DENV2-infected (MOI 5, 72 hpi) C6/36 cells or infected mosquito
cells treated with 20 μM of GW4869 inhibitor] produced fresh
EVs that were capable of transmigration and infecting naïve
HUVEC cells (plated in lower chambers) (Fig. 4J). HUVEC cells
incubated with inhibitor- (20 μM) treated EVs showed reduced
DENV2 loads (at 48 hpi) in comparison with the untreated in-
fectious EV fractions (Fig. 4J). Infections using the DENV2 lab-
oratory viral stocks (with known titers, we used 5 MOI) served
as internal controls (Fig. 4J). Furthermore, IP performed with
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Fig. 4. RNAi-mediated silencing or antibody blocking of Tsp29Fb or treatment with GW4869 inhibitor affects DENV2 burden in mosquito cells and EVs. qRT-
PCR analysis showing expression of A. aegypti Tsp29Fb to reveal silencing efficiency (A) or viral burden (B) in whole-cell lysates or EVs derived from DENV2-
infected (MOI 2, 24 hpi) Aag-2 cells treated with mock or Tsp29Fb-dsRNA (n = 6). (C) Immunoblotting analysis showing levels of A. aegypti Tsp29Fb or viral
E-protein in whole-cell lysates or EVs derived from DENV2-infected (MOI 2, 24 hpi) Aag-2 cells treated with mock or Tsp29Fb-double-stranded RNA. qRT-PCR
(D and E) (n = 3) or immunoblotting (F) analysis showing viral burden in EVs (D and F) or whole-cell lysates (E and F) derived from DENV2-infected (MOI 5,
72 hpi) C6/36 cells treated with CD63 (Tsp29Fb) antibody at different doses (of 5 and 10 μg). Untreated, but DENV2-infected (MOI 2, 72 hpi) C6/36 cells were
used as mock controls in D–F. qRT-PCR (G) (n = 4) or immunoblotting (H) analysis showing viral burden in EVs (G and H) or whole-cell lysates (H) derived from
DENV2-infected (MOI 2) C6/36 cells at 72 hpi (G) or at 18 or 24 hpi (H), treated with GW4869 inhibitor at different doses (of 5–20 μM). EVs or whole-cell lysates
derived from DMSO-treated DENV2-infected C6/36 cells were used as controls in G and H. (I) qRT-PCR analysis showing viral burden in naïve C6/36 cells at
48 hpi, (reinfection) upon treatment with EVs derived from DMSO- or GW4869-treated DENV2-infected (MOI 2, 72 hpi) C6/36 cells (n = 4). (J) qRT-PCR analysis
showing viral loads at 48 hpi in HUVEC cells in a transwell assay performed with C6/36 cells (in upper chamber) and naïve HUVEC cells (in lower chamber)
treated with EVs derived from DENV2-infected (MOI 2, 72 hpi) C6/36 cells (25 μL, in upper chamber) for 4 h in the presence or absence of GW4869 (20 μM). C6/
36 cells infected with DENV2 laboratory stocks with known titers were used as internal controls (n = 4). Tsp29Fb or DENV2 capsid mRNA levels were nor-
malized to mosquito (A, B, D, E, and I), or human (J) actin levels, but in G, DENV2 loads were normalized to total RNA. P value determined by Student’s two-
tail t test is shown. (K) Immunoblotting analysis of CD63 (Tsp29Fb)-IP proteins with 4G2 antibody and EVs or whole-cell lysates derived from DMSO- or
GW4869-treated DENV2-infected (MOI 2, 24 hpi) C6/36 cells. Tsp29Fb and DENV2 E-protein molecular mass is indicated in kilodaltons. Coomassie-stained gel
images showing total protein profiles in C, F, H, and K serve as loading control for the respective immunoblots.
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CD63 antibody and lysates fromDENV2-infected (MOI 5, 24 hpi)
C6/36 cells treated with GW4869 inhibitor (15 μM) or DMSO
control confirmed that blocking of EV release affects the direct
interaction of Tsp29Fb with DENV2 E-protein in both cells and
EVs (Fig. 4K). These data further suggest that direct interaction of
Tsp29Fb with E-protein is not only required for DENV2 infection
and pathogenesis in the arthropod host, but is also essential for
transmission of infectious EVs to the human host.
Discussion
The modes or the molecular determinants that participate in the
transmission of arthropod-borne flavivirus from the vector to the
vertebrate host are not completely understood. To address this
basic but very fundamental question, we explored the role of EVs
in flavivirus transmission. EVs, including exosomes, have been
shown as vehicles of transmission for a variety of microorgan-
isms, and recent findings of hepatitis C virus transmission
through hepatic exosomes have provided new insights into hep-
atitis drug discovery (19, 21, 39–41). The recent discoveries of
functional RNA, miRNA, and proteins in the EVs/exosomes has
increased the attention that has lead to the emergence of nu-
merous studies in identifying novel molecules present in the
EVs/exosomes (12–16, 39, 42). Because of the occurrence of
RNA in the EVs, we hypothesized whether arthropod EVs are
also carriers of viral RNA from mosquito-borne flaviviruses.
In this study we have shown the presence of a ull-length DENV2
genome in EVs and that DENV2/DENV3 infectious viral RNA
and proteins are also securedly contained and transported to
the mammalian cells through mosquito cell-derived EVs. The
genome RNA of flaviviruses is single-stranded with ∼11 kb in
length that is infectious with positive polarity encoding the viral
proteins required for RNA replication (43–45). Our data sug-
gest that perhaps the full-length genomes of other serotypes
of DENVs and other related flavivirus genomes are securedly
contained in arthropod EVs for transmission. For DENVs (se-
rotypes 1–4), an antibody-dependent enhancement (ADE) of
viral replication was noted in vitro that lead to the understanding
of pathogenesis of dengue in animal models and humans (46–
48). A specific range of antibody titer has been shown to enhance
such viral replication (46–48). In humans, although suspected,
such ADE leading to severe disease has not been shown to occur
(46). Nonneutralizing antiviral proteins (i.e., the antibodies) fa-
cilitate virus entry into the host cells by binding to the Fc re-
ceptors in the plasma membrane, thereby leading to increased
infectivity and ADE (49). We have previously shown that tick-
borne Langat virus RNA and proteins are securedly contained
inside tick exosomes and that exosome-mediated Langat virus
transmission to recepient cells is through receptor-dependent
endocytosis that requires clathrin (19). We assume that the
presence of DENV2/DENV3 RNA and proteins inside EVs
perhaps escape the viral check points by host-neutralizing or
nonneutralizing antibodies. This could allow enhanced fusion
of EVs on recepient cells through clathrin-dependent receptor-
mediated endocytosis and thereby facilitate infection. We as-
sume that EV-mediated transmission may result in ADE of
DENV replication.
In our multiple cryo-EM analyses, we did not find the pres-
ence of intact virions/viral particles inside or outside of the EVs
or in the PBS suspensions, as we have used 72 hpi as the time point
for analysis. To make virus preparations, concentrated supernatants
from longer times of infection (7–14 dpi) with higher titers (109 to
1012 PFU/mL) and centrifugal forces of 200,000 × g have been used
(50) that are not similar to the one used in our EV preparations (SI
Appendix, Fig. S2). To avoid longer incubation days and peak of
infection resulting in cell death, we considered performing all
experiments at 72 hpi; however, longer times of infection (days
7–14) may reveal differences in the DENV2-infected group.
Mosquito cell-derived EVs were found to be of heterogenous
population, varying from sizes of 30–250 nm; however, fewer of
them were with sizes of 250–350 nm and could be considered as
EVs. The quantitative analysis of the cryo-EM data suggested a
smaller number of large-size EVs in the DENV2-infected (72 hpi)
group compared with the number of EVs from the uninfected
group. In addition, the DENV2-infected smaller EVs/exosomes of
30- to 100-nm size were abundantly present, suggesting that viral
RNA and proteins are perhaps more secured in smaller EVs due
to greater integrity/stability during release from cells or during
fusion with recipient cells.
EVs isolated from the density gradient method that also
resulted in purified EV preparations (18), showed the presence
of HSP70, the EV-enriched protein. Detection of DENV2 E-
protein in the same fraction suggested that perhaps these are
EVs/exosomes, with size ranges of 50–100 nm that were analyzed
as the highest percentages with quantitative estimation from
cryo-EM images. EV quantification largely relies on their physical
characteristics or properties—such as size, mass, and density—
or the membrane proteins presented on their surface as cargo.
For other quantification methods, such as Nanodrop or Nanosight,
high concentrations of EVs are required and the results are
mostly variable (51, 52). Increase in the presence of a specific EV
biomarker has been correlated with a general increase in vesicle
secretion, or rather with an increase in biomarker density on the
surface of vesicles (51, 52). However, the differential cargo loading
on EVs each time would perhaps suggest variability in using bio-
markers for quantification. The reference to the total protein con-
centration (determined by the BCAmethod) each time has given us
very reliable and consistent results on the routine isolation of EVs.
The abundant amount of E-protein in arthropod EVs in compari-
son with the cell lysates suggests the higher packaging of E-protein
for transmission to human and other vertebrate host cells. In ad-
dition, we assume that an abundant amount of viral RNA and
proteins inside cells may randomly get trafficked into EVs. We
hypothesize that dissemination of infectious EVs within mosquitoes
from hemolymph to the salivary glands and subsequently to the
mosquito saliva may efficiently facilitate the transmission of the
infectious viral RNA and proteins to the vertebrate host through
an infected arthropod bite site during blood feeding.
The observation of no differences in the viral loads in
4G2 antibody-beads binding assay suggests that E-protein is
contained inside the EVs. If E-protein or viral particles are
present outside the EVs as contaminants, the 4G2 antibody
could bind E-protein, resulting in lower viral loads in comparison
with the isotype antibody-treated or untreated controls. Treat-
ment of DENV2 viral stocks with 4G2 antibody showed binding
of surface-exposed E-protein, but not in the EV group, as E-
protein was contained inside EVs and hence was unavailable to
bind 4G2 antibody. These differences in 4G2 antibody binding to
E-protein suggest that E-protein is securely contained inside the
arthropod EVs. RNaseA-treatment assays were in agreement
with the antibody-beads binding assay that further suggests no
RNA binding outside of EVs or no availibility of free viral RNA
being presented outside of the EVs. If viral RNA was present in
PBS suspensions containing EVs, we should expect an enhanced
viral load in samples not treated with RNaseA in comparison
with the treated group. These data are further supported by
native-PAGE immunostaining with 4G2 antibody and ELISAs
that showed more intense signal in the Triton X-100–treated
group in comparison with the untreated controls. Native-
PAGE analysis indicated detection of either higher complexes
of E-protein as dimer or oligomers or perhaps the presence of
viral polyprotein (at higher molecular mass) under nonreducing
conditions and in the native state. The observation of lower mo-
lecular mass of E-protein (as detected by 4G2 antibody) upon
Triton X-100 treatment suggests lysis of EVs and breakdown of
higher molecular mass of E-proteins. In addition, the observation of
no detection of fluorescent signal (with 4G2 antibody), no plaque















formation, and no amplification of capsid mRNA transcripts in EV-
free or EDS further suggests that the preparations were clean and
contained viral RNA and proteins inside the EVs. Infection of
different cell lines (mouse and human), including mosquito cells
with infectious arthropod-derived EVs, suggest that the viral RNA
and proteins are contained inside the EVs that are capable of
transmission and replication in recipient cells.
HSPs include both constitutive and stress-inducible members
that interact with native and denatured proteins to facilitate the
proper folding of native proteins or refolding of the denatured
proteins (27, 28). In addition to their essential roles in in-
tracellular trafficking, they also prevent the cytotoxic aggregation
or misfoldings of the aberrantly folded proteins (27, 28). HSPs
have been shown to play diverse behavioral, biochemical, and
physiological roles in insects and one of the most essential cel-
lular responses is a rapid increase in expression of HSPs upon
stress (30). HSP70 is the most widely studied responder to heat and
other stresses and at least 12 HSP proteins have been shown to
abundantly increase in response to heat/temperature (53–55). The
levels of mosquito HSP70s have been documented to increase
during several environmental stresses, and several hsp genes are up-
regulated following a blood meal in mosquitoes (53–55). Up-
regulation of HSP70 homologs upon DENV2 infection suggested
a protective role of this molecule during DENV2-induced stress.
The presence of only one isoform (XM_019672019) of HSP70 in
EVs suggests the importance of this molecule possibly in the chap-
erone activity inside EVs. The observation of no effect on
DENV2 loads in EVs upon treatment with VER-155008 inhibitor
suggests that HSP70 is perhaps not required for DENV2 replication
in cells and release into EVs. In addition, the observation of no
differences in the DENV2 loads in naïve C6/36 cells upon treatment
with infectious EVs [derived from HSP70-inhibitor–treated and
DENV2-infected (MOI 5, 72 hpi) C6/36 cells] suggests that
HSP70 may not be required for EV-mediated transmission of
DENV2 RNA and proteins.
Identification of the transmembrane/tetraspanin domain-
containing glycoprotein Tsp29Fb from A. aegypti mosquito cells
and EVs derived from both A. aegypti (Aag-2) and A. albopictus
(C6/36) cells indicated the presence of this molecule in both
species. Up-regulation of Tsp29Fb upon DENV2 infection at
both mRNA and protein levels and in both cells and EVs lysates
confirmed the importance of this molecule in mediating DENV2
infection and transmission of infectious viral RNA and proteins
via EVs. Identification and characterization of this arthropod
EV-enriched marker provides information on the molecular
determinants that facilitate transmission of DENV2 from vector
to the vertebrate host. Furthermore, the direct interaction and
coassociation of Tsp29Fb with DENV2 E-protein suggests a
potential role of this molecule in mediating DENV2 replication
and transmission via the arthropod endo-exosomal pathway. The
enriched signal for E-protein in both IP assays could be because
of the enhanced production and more availability of Tsp29Fb to
physically bind with DENV2 E-protein in cells compared with
the EV fractions. Trafficking of other required cargo may also
limit the loading of more Tsp29Fb in DENV2-infected EVs (16,
22, 36, 56, 57). Silencing of Tsp29Fb in cells showed a significant
reduction in DENV2 cellular loads and significantly reduced
export of the viral RNA and E-protein in EVs. Furthermore,
functional blocking of Tsp29Fb clearly showed reduced
DENV2 loads in both EVs and cells. These data clearly showed
the prominence of this arthropod molecule in mediating
DENV2 replication, release, and transmission via EVs.
The use of exosome release inhibitor GW4869 at lower tested
doses of 10–20 μM further confirmed that DENV2 transmission
is mediated via EV release. The inhibitor treatment dramatically
decreased the DENV2 capsid mRNA and E-protein. In addition,
blocking of EVs/exosome release by GW4869 reduced the in-
fectious viral RNA and protein transport, thereby dramatically
blocking the transmission to human blood endothelial cells. The
direct interaction of the viral E-protein with Tsp29Fb was also
affected by treatment with GW4869, suggesting a role for this
arthropod marker in the EVs/exosome release pathway. It would
be an interesting future avenue to investigate the mechanism of
this viral inhibition through blocking the release of EVs from
arthropod saliva. The finding that inhibition of EVs/exosome
release upon GW4869 treatment in arthropod cells suggests the
presence of neutral sphingomyelinase in mosquitoes. Overall,
our study suggests that inhibition of arthropod tetraspanin
domain-containing glycoprotein Tsp29Fb or inhibition of EVs/
exosome release through the GW4869 inhibitor are both po-
tential therapeutics to block transmission of DENV2 and per-
haps other mosquito-borne flaviviruses.
Materials and Methods
A. albopictus (C6/36 cells) and the African Green Monkey kidney Vero cell
line were obtained from ATCC. The Aedes aegypti (Aag-2) cell line was
obtained from T.M.C.’s laboratory. Mouse Mo-DCs, HaCaT cells, and HUVECs
were obtained from the Piotr Kraj, Loree Heller, and John Catravas labora-
tories, respectively, Old Dominion University, Norfolk, Virginia. DENV2 El
Salvador strain (TVP2176) was obtained from John F. Anderson, Connecticut
Agricultural Experiment Station, New Haven, Connecticut. DENV3 (DENV-3/
US/BID-V1619/2005) or the DENV2 New Guinea C strains were obtained from
BEI Resources. Detailed materials and methods can be found in SI Appendix.
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